MDXH
MDxHealth SA
$0.5420
-7.67%
$27.8M
No data for this timeframe.
Vol
Market Cap$27.8M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (83%)
Inst. Holders1 funds
Inst. Value$179.4K
SEC Reports3
Press Releases1
Recent Activity
Jun 1, 2026
Insider
McGarrity Michael was granted 329,800 shares
Chief Executive Officer
Jun 1, 2026
Insider
Sollee Joseph was granted 83,000 shares
See Remarks
Jun 1, 2026
Insider
Bellano John was granted 116,000 shares
Chief Commercial Officer
May 26, 2026
short_volume
Short Volume: MDXH — 59.2% short (0.4M / 0.7M)
Short: 386,677 | Exempt: 12,821 | TRF Vol: 653,560 | Short Ratio: 59.2% | Off-exchange volume (dark
Apr 30, 2026
SEC
MDxHealth filed a 6-K furnishing proxy materials for its May 28, 2026 ordinary and extraordinary general shareholders' m
6-K — Impact 3/10
Apr 13, 2026
SEC
MDxHealth SA executives Ron Kalfus (CFO), John Bellano (CCO), and Michael McGarrity (CEO) each filed a Form 3 and grante
3 — Impact 2/10
Apr 11, 2026
SEC
Donnie (Don) M. Hardison, an officer and director of MDxHealth SA, filed a Form 3 to report his initial beneficial owner
3 — Impact 3/10
Mar 16, 2026
Press
Mdxhealth highlighted new data from the Oxford-led ProMPT study showing its GPS mdx genomic test can predict favorable o
Impact 7/10
Price Targets
$2.90
+434.9% upside
Strong Buy
Current $0.5422
Low $1.00
Median $3.00
High $5.00
5 analysts
$1.00
$5.00
Analyst Ratings
4Strong Buy
6Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 14, 2026 | Lake Street | MAINTAIN | Buy → Buy |
| May 14, 2026 | TD Cowen | MAINTAIN | Buy → Buy |
| May 14, 2026 | BTIG | MAINTAIN | Buy → Buy |
| Dec 23, 2025 | BTIG | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.19 ▼ -61.7% | $-0.25 — $-0.16 | -39% YoY | 5 |
| Next Q | $-0.16 ▼ -62.0% | $-0.20 — $-0.12 | -1% YoY | 5 |
| Current FY | $-0.46 ▼ -43.8% | $-0.46 — $-0.46 | -6% YoY | 1 |
| Next FY | $-0.38 ▼ -192.3% | $-0.38 — $-0.38 | 17% YoY | 1 |
Latest Reports
NEUTRAL
6-K
3/10
MDxHealth filed a 6-K furnishing proxy materials for its May 28, 2026 ordinary and extraordinary general shareholders' m
Apr 30, 2026
NEUTRAL
3
2/10
MDxHealth SA executives Ron Kalfus (CFO), John Bellano (CCO), and Michael McGarrity (CEO) each filed a Form 3 and grante
Apr 13, 2026
BULLISH
Press
7/10
Mdxhealth highlighted new data from the Oxford-led ProMPT study showing its GPS mdx genomic test can predict favorable o
Mar 16, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MARSHALL WACE, LLP | $179.4K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 1, 2026 | McGarrity Michael | A | $0.00 |
| Jun 1, 2026 | Sollee Joseph | A | $0.00 |
| Jun 1, 2026 | Bellano John | A | $0.00 |
| Jun 1, 2026 | Windels Hilde | A | $0.00 |
| Jun 1, 2026 | Holder Michael | A | $0.00 |
1 institutional holders with $179.4K total value (38,589 shares) as of 2025-Q3. Top holders: MARSHALL.
Top Institutional Holders — 2025-Q3
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MARSHALL WACE, LLP | 38,589 | $179.4K | 100.0% | — |
9 unique insiders with 9 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 1, 2026 | McGarrity Michael | Chief Executive Officer | AWARD | 329,800 | — | — |
| Jun 1, 2026 | Sollee Joseph | See Remarks | AWARD | 83,000 | — | — |
| Jun 1, 2026 | Bellano John | Chief Commercial Officer | AWARD | 116,000 | — | — |
| Jun 1, 2026 | Windels Hilde | Director | AWARD | 10,000 | — | — |
| Jun 1, 2026 | Holder Michael | Director | AWARD | 10,000 | — | — |
| Jun 1, 2026 | Siegel Sanford Jay | Director | AWARD | 10,000 | — | — |
| Jun 1, 2026 | Hoffman Koen | Director | AWARD | 10,000 | — | — |
| Jun 1, 2026 | HARDISON DON M | Director | AWARD | 10,000 | — | — |
| Jun 1, 2026 | OConnell Brendan | VP, Finance and Accounting | AWARD | 35,000 | — | — |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 2.7/10.
NEUTRAL
6-K
3/10
MDxHealth filed a 6-K furnishing proxy materials for its May 28, 2026 ordinary and extraordinary gen
Apr 30, 2026
NEUTRAL
3
2/10
MDxHealth SA executives Ron Kalfus (CFO), John Bellano (CCO), and Michael McGarrity (CEO) each filed
Apr 13, 2026
NEUTRAL
3
3/10
Donnie (Don) M. Hardison, an officer and director of MDxHealth SA, filed a Form 3 to report his init
Apr 11, 2026
Current analyst consensus: Strong Buy (83% buy). Based on 12 analysts: 4 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$2.90 mean target
+434.9% upside
Strong Buy (1.67)
$1.00 Low
$5.00 High
| Metric | Value |
|---|---|
| Current Price | $0.5422 |
| Target Low | $1.00 |
| Target Mean | $2.90 |
| Target Median | $3.00 |
| Target High | $5.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (1.67) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.19 | $-0.25 | $-0.16 | -38.6% | -61.7% | 0↑ 4↓ | $0.0B | -1.9% | 5 |
| Next Q 2026-09-30 |
$-0.16 | $-0.20 | $-0.12 | -1.3% | -62.0% | 1↑ 4↓ | $0.0B | 1.8% | 5 |
| Current FY 2026-12-31 |
$-0.46 | $-0.46 | $-0.46 | -6.3% | -43.8% | 0↑ 1↓ | $0.1B | 4.2% | 1 |
| Next FY 2027-12-31 |
$-0.38 | $-0.38 | $-0.38 | 17.4% | -192.3% | 0↑ 1↓ | $0.1B | 12.5% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.194 | |
| 7d ago | $-0.120 | -0.074 |
| 30d ago | $-0.120 | -0.074 |
| 60d ago | $-0.120 | -0.074 |
| 90d ago | $-0.067 | -0.127 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 14, 2026 | Lake Street | MAINTAIN | Buy | Buy |
| May 14, 2026 | TD Cowen | MAINTAIN | Buy | Buy |
| May 14, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Dec 23, 2025 | BTIG | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% | |
| May 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Apr 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 26, 2026
short_volume
Short Volume: MDXH — 59.2% short (0.4M / 0.7M)
Short: 386,677 | Exempt: 12,821 | TRF Vol: 653,560 | Short Ratio: 59.2% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: MDXH — 58.0% short (0.8M / 1.5M)
Short: 847,040 | Exempt: 156,652 | TRF Vol: 1,459,496 | Short Ratio: 58.0% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: MDXH — 59.1% short (3.7M / 6.2M)
Short: 3,664,311 | Exempt: 480,863 | TRF Vol: 6,200,777 | Short Ratio: 59.1% | Off-exchange volume (dark pool + OTC)
May 13, 2026
earnings
Mdxhealth Reports Q1-2026 Results
<p align="center"><b>Mdxhealth Reports Q1-2026 Results</b></p>
May 13, 2026
earnings_calendar
MDXH Q1 2026 Earnings Scheduled — 2026-05-13
Apr 30, 2026
earnings
Mdxhealth to Release First Quarter 2026 Financial Results on May 13
Mdxhealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the first quarter ende
Mar 16, 2026
fda
Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026
<p align="center"><b>Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes
Feb 26, 2026
earnings_calendar
MDXH Q4 2025 Earnings After Market Close — 2026-02-26